China Health Labs & Diagnostics Ltd. Announces Engagement of Langda Consulting For Investor Relations Services
September 09 2011 - 9:00AM
PR Newswire (Canada)
TORONTO, Sept. 9, 2011 /CNW/ -- TSX-V: CHO OTCQX: CHLBF
TORONTO, Sept. 9, 2011 /CNW/ - China Health Labs & Diagnostics
Ltd. ("China Health" or the "Company") (TSXV: CHO) (OTCQX: CHLBF)
is pleased to announce that it has engaged Langda Consulting
("Langda") to provide China Health with strategic investor
relations services focused on communities and investors that have
an interest in China-based companies. Langda will work in
collaboration with TMX Equicom to deliver the Company's investor
relations program. Langda is a Toronto based consulting firm
specializing in providing professional consulting services to
China-based companies in raising capital, developing investment
opportunities and increasing market awareness in Canada and the
United States. Under the terms of the consulting services
agreement, China Health will pay Langda a monthly fee of $3,600
plus HST for such services for an initial term of six months.
Neither Langda nor any of its principals have an ownership
interest, directly or indirectly, in China Health or its
securities, nor has the Company granted Langda or its principals
any rights or options to acquire any such interests. About China
Health Labs & Diagnostics Ltd. China Health, operating in China
as the Biochem Group, is a leading diagnostic lab solution provider
for the public healthcare industry in China. The Company develops
and sells Biochem Group branded and third-party medical diagnostic
products and services to diagnostic facilities in China. Customers
include large urban hospitals, rural hospitals, Chinese military
and rescue operations, the Beijing government and third-party
distributors. In 2010, China Health had revenues of approximately
$33.7 million, and intends to expand its business by focusing its
efforts on expanding its sales network in three areas where it
provides proprietary solutions, has limited competition and that
are supported by Chinese government policy and budgets: BK Clinlab
total lab solutions for rural hospitals and clinics, POCT solutions
for military and emergency rescue services, and food safety
solutions for large cities in China. Neither TSX Venture Exchange
nor its Regulation Services Provider (as that term is defined in
the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release. FORWARD LOOKING
INFORMATION This press release contains forward-looking statements
and information that are based on the beliefs of management and
reflect China Health's current expectations. When used in
this press release, the words "estimate", "project", "belief",
"anticipate", "intend", "expect", "plan", "predict", "may" or
"should" and the negative of these words or such variations thereon
or comparable terminology are intended to identify forward-looking
statements and information. The forward-looking statements
and information in this press release includes information relating
to the expansion of the Company's business through its sales
network in areas where it has proprietary products, limited
competition and strong government support. The
forward-looking information is based on certain assumptions, which
could change materially in the future, including the assumption
that the Company will be able to expand its sales network and
business. Such statements and information reflect the current
view of China Health with respect to risks and uncertainties that
may cause actual results to differ materially from those
contemplated in those forward-looking statements and
information. By their nature, forward-looking statements
involve known and unknown risks, uncertainties and other factors
which may cause our actual results, performance or achievements, or
other future events, to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, among others, the
risk that the Company may not be able to expand its business as
expected through its sales network in any of the areas in which it
has proprietary products, limited competition and strong government
support. China Health cautions that the foregoing list of
material factors is not exhaustive. When relying on China
Health's forward-looking statements and information to make
decisions, investors and others should carefully consider the
foregoing factors and other uncertainties and potential
events. China Health has assumed a certain progression, which
may not be realized. It has also assumed that the material
factors referred to above will not cause such forward-looking
statements and information to differ materially from actual results
or events. However, the list of these factors is not
exhaustive and is subject to change and there can be no assurance
that such assumptions will reflect the actual outcome of such items
or factors. THE FORWARD-LOOKING INFORMATION CONTAINED IN THIS PRESS
RELEASE REPRESENTS THE EXPECTATIONS OF CHINA HEALTH AS OF THE DATE
OF THIS PRESS RELEASE AND, ACCORDINGLY, IS SUBJECT TO CHANGE AFTER
SUCH DATE. READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON
FORWARD-LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS
INFORMATION AS OF ANY OTHER DATE. WHILE CHINA HEALTH MAY
ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY
PARTICULAR TIME EXCEPT AS REQUIRED IN ACCORDANCE WITH APPLICABLE
LAWS. To view this news release in HTML formatting, please use the
following URL:
http://www.newswire.ca/en/releases/archive/September2011/09/c9753.html
p Babak Pedrambr/ Investor Relationsbr/ TMX Equicom Groupbr/ T:
(416) 815-0700 ext. 264br/ Email: a
href="mailto:bpedram@equicomgroup.com"bpedram@equicomgroup.com/a /p
Copyright
China Health Labs And Diagnostics Ltd (TSXV:CHO)
Historical Stock Chart
From Jun 2024 to Jul 2024
China Health Labs And Diagnostics Ltd (TSXV:CHO)
Historical Stock Chart
From Jul 2023 to Jul 2024